1.No difference in factual or conceptual recall comprehension for tablet, laptop, and handwritten note-taking by medical students in the United States: a survey-based observational study
Warren WIECHMANN ; Robert EDWARDS ; Cheyenne LOW ; Alisa WRAY ; Megan BOYSEN-OSBORN ; Shannon TOOHEY
Journal of Educational Evaluation for Health Professions 2022;19(1):8-
Purpose:
Technological advances are changing how students approach learning. The traditional note-taking methods of longhand writing have been supplemented and replaced by tablets, smartphones, and laptop note-taking. It has been theorized that writing notes by hand requires more complex cognitive processes and may lead to better retention. However, few studies have investigated the use of tablet-based note-taking, which allows the incorporation of typing, drawing, highlights, and media. We therefore sought to confirm the hypothesis that tablet-based note-taking would lead to equivalent or better recall as compared to written note-taking.
Methods:
We allocated 68 students into longhand, laptop, or tablet note-taking groups, and they watched and took notes on a presentation on which they were assessed for factual and conceptual recall. A second short distractor video was shown, followed by a 30-minute assessment at the University of California, Irvine campus, over a single day period in August 2018. Notes were analyzed for content, supplemental drawings, and other media sources.
Results:
No significant difference was found in the factual or conceptual recall scores for tablet, laptop, and handwritten note-taking (P=0.61). The median word count was 131.5 for tablets, 121.0 for handwriting, and 297.0 for laptops (P=0.01). The tablet group had the highest presence of drawing, highlighting, and other media/tools.
Conclusion
In light of conflicting research regarding the best note-taking method, our study showed that longhand note-taking is not superior to tablet or laptop note-taking. This suggests students should be encouraged to pick the note-taking method that appeals most to them. In the future, traditional note-taking may be replaced or supplemented with digital technologies that provide similar efficacy with more convenience.
2.Perioperative critical care management for patients with aneurysmal subarachnoid hemorrhage.
Kiwon LEE ; H Alex CHOI ; Nancy EDWARDS ; Tiffany CHANG ; Robert N SLADEN
Korean Journal of Anesthesiology 2014;67(2):77-84
Despite significant regional and risk factor-related variations, the overall mortality rate in patients suffering from aneurysmal subarachnoid hemorrhage (SAH) remains high. Compared to ischemic stroke, which is typically irreversible, hemorrhagic stroke tends to carry a higher mortality, but patients who do survive have less disability. Technologies to monitor and treat complications of SAH have advanced considerably in recent years, but good long-term functional outcome still depends on prompt diagnosis, early aggressive management, and avoidance of premature withdrawal of support. Endovascular procedures and open craniotomy to secure a ruptured aneurysm represent some of the numerous critical steps required to achieve the best possible result. In this review, we have attempted to provide a contemporary, evidence-based outline of the perioperative critical care management of patients with SAH. This is a challenging and potentially fatal disease with a wide spectrum of severity and complications and an often protracted course. The dynamic nature of this illness, especially in its most severe forms, requires considerable flexibility in clinician management, especially given the panoply of available treatment modalities. Judicious hemodynamic monitoring and adaptive therapy are essential to respond to the fluctuating nature of cerebral vasospasm and the varying oxygen demands of the injured brain that may readily induce acute or delayed cerebral ischemia.
Aneurysm, Ruptured
;
Brain
;
Brain Ischemia
;
Craniotomy
;
Critical Care*
;
Early Diagnosis
;
Endovascular Procedures
;
Hemodynamics
;
Humans
;
Intensive Care Units
;
Mortality
;
Oxygen
;
Pliability
;
Stroke
;
Subarachnoid Hemorrhage*
;
Vasospasm, Intracranial
3.Translation: Non-HDL Cholesterol Shows Improved Accuracy for Cardiovascular Risk Score Classification Compared to Direct or Calculated LDL Cholesterol in a Dyslipidemic Population.
Hendrick E VAN DEVENTER ; W Greg MILLER ; Gary L MYERS ; Ikunosuke SAKURABAYASHI ; Lorin M BACHMANN ; Samuel P CAUDILL ; Andrzej DZIEKONSKI ; Selvin EDWARDS ; Mary M KIMBERLY ; William J KORZUN ; Elizabeth T LEARY ; Katsuyuki NAKAJIMA ; Masakazu NAKAMURA ; Robert D SHAMBUREK ; George W VETROVEC ; G Russell WARNICK ; Alan T REMALEY
Laboratory Medicine Online 2011;1(3):121-131
BACKGROUND: Our objective was to evaluate the accuracy of cardiovascular disease (CVD) risk score classification by direct LDL cholesterol (dLDL-C), calculated LDL cholesterol (cLDL-C), and non-HDL cholesterol (non-HDL-C) compared to classification by reference measurement procedures (RMPs) performed at the CDC. METHODS: Weexamined 175 individuals, including 138 with CVD or conditions that may affect LDL-C measurement. dLDL-C measurements were performed using Denka, Kyowa, Sekisui, Serotec, Sysmex, UMA, and Wako reagents. cLDL-C was calculated by the Friedewald equation, using each manufacturer's direct HDL-C assay measurements, and total cholesterol and triglyceride measurements by Roche and Siemens (Advia) assays, respectively. RESULTS: For participants with triglycerides <2.26 mmol/L (<200 mg/dL), the overall misclassification rate for the CVD risk score ranged from 5% to 17% for cLDL-C methods and 8% to 26% for dLDL-C methods when compared to the RMP. Only Wako dLDL-C had fewer misclassifications than its corresponding cLDL-C method (8% vs 17%; P<0.05). Non-HDL-C assays misclassified fewer patients than dLDL-C for 4 of 8 methods (P<0.05). For participants with triglycerides > or =2.26 mmol/L (> or =200 mg/dL) and <4.52 mmol/L (<400 mg/dL), dLDL-C methods, in general, performed better than cLDL-C methods, and non-HDL-C methods showed better correspondence to the RMP for CVD risk score than either dLDL-C or cLDL-C methods. CONCLUSIONS: Except for hypertriglyceridemic individuals, 7 of 8 dLDL-C methods failed to show improved CVD risk score classification over the corresponding cLDL-C methods. Non-HDL-C showed overall the best concordance with the RMP for CVD risk score classification of both normal and hypertriglyceridemic individuals.
Cardiovascular Diseases
;
Cholesterol
;
Cholesterol, LDL
;
Humans
;
Indicators and Reagents
;
Triglycerides
4.Identification of new genetic risk factors for prostate cancer.
Michelle GUY ; Zsofia KOTE-JARAI ; Graham G GILES ; Ali Amin Al OLAMA ; Sarah K JUGURNAUTH ; Shani MULHOLLAND ; Daniel A LEONGAMORNLERT ; Stephen M EDWARDS ; Jonathan MORRISON ; Helen I FIELD ; Melissa C SOUTHEY ; Gianluca SEVERI ; Jenny L DONOVAN ; Freddie C HAMDY ; David P DEARNALEY ; Kenneth R MUIR ; Charmaine SMITH ; Melisa BAGNATO ; Audrey T ARDERN-JONES ; Amanda L HALL ; Lynne T O'BRIEN ; Beatrice N GEHR-SWAIN ; Rosemary A WILKINSON ; Angela COX ; Sarah LEWIS ; Paul M BROWN ; Sameer G JHAVAR ; Malgorzata TYMRAKIEWICZ ; Artitaya LOPHATANANON ; Sarah L BRYANT ; null ; null ; null ; Alan HORWICH ; Robert A HUDDART ; Vincent S KHOO ; Christopher C PARKER ; Christopher J WOODHOUSE ; Alan THOMPSON ; Tim CHRISTMAS ; Chris OGDEN ; Cyril FISHER ; Charles JAMESON ; Colin S COOPER ; Dallas R ENGLISH ; John L HOPPER ; David E NEAL ; Douglas F EASTON ; Rosalind A EELES
Asian Journal of Andrology 2009;11(1):49-55
There is evidence that a substantial part of genetic predisposition to prostate cancer (PCa) may be due to lower penetrance genes which are found by genome-wide association studies. We have recently conducted such a study and seven new regions of the genome linked to PCa risk have been identified. Three of these loci contain candidate susceptibility genes: MSMB, LMTK2 and KLK2/3. The MSMB and KLK2/3 genes may be useful for PCa screening, and the LMTK2 gene might provide a potential therapeutic target. Together with results from other groups, there are now 23 germline genetic variants which have been reported. These results have the potential to be developed into a genetic test. However, we consider that marketing of tests to the public is premature, as PCa risk can not be evaluated fully at this stage and the appropriate screening protocols need to be developed. Follow-up validation studies, as well as studies to explore the psychological implications of genetic profile testing, will be vital prior to roll out into healthcare.
Genetic Predisposition to Disease
;
genetics
;
Genetic Testing
;
Humans
;
Kallikreins
;
genetics
;
Male
;
Membrane Proteins
;
genetics
;
Prostatic Neoplasms
;
diagnosis
;
genetics
;
Prostatic Secretory Proteins
;
genetics
;
Protein-Serine-Threonine Kinases
;
genetics
;
Risk Factors